Theme Settings
Color Scheme
Light
Dark
Layout Mode
Fluid
Boxed
Topbar Color
Light
Dark
Brand

GEPIA 3

GEPIA3 introduces innovative modules that enhance analytical capabilities, including:

  • a) a comprehensive drug sensitivity analysis that integrates patient-derived data from TCGA with cell-line screening data for over 1,000 therapeutic agents,
  • b) offering advanced analyses of gene/protein interactions, as well as regulatory networks across multiple cancer types,
  • c) incorporating RNA alterations—such as allele-specific expression, alternative promoters and RNA fusions—based on Pan-Cancer Analysis of Whole Genomes (PCAWG) project,
These updates provide an effective and comprehensive platform for pan-cancer multi-omics analysis, empowering researchers to mine large-scale genomic datasets for exploring cancer mechanisms, therapeutic targets and precision medicine strategies.

How to cite GEPIA 3

Yujian Kang, Lingjie Pan, Yiyu Liu, Zhengqin Rong, Jiaxi Liu, Fenglin Liu*. GEPlA3: Enhanced Drug Sensitivity and Interaction Network Analysis for Cancer Research.

Contact us

If any question about the GEPIA3, please contact us: lfl@pku.edu.cn

Acknowledgement

The RNA-Seq datasets GEPIA3 used is based on the UCSC Xena project ( http://xena.ucsc.edu ), which are computed by a standard pipeline.

This project was supported by grants from Beijing Advanced Innovation Center for Genomics at Peking University, Key Technologies R&D Program (2016YFC0900100) and National Natural Science Foundation of China (81573022, 31530036).

License Statement: All content on this website is freely available to all users, including for commercial use.